Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer

NCT03698383 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

15

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer
Metastatic Breast Cancer

Interventions

DRUG: Trastuzumab biosimilars(Herzuma), Gedatolisib

Sponsor

Korean Cancer Study Group